Beneath the individual filings and trial readouts, a deeper structural pattern is forming. The swarm's four highest-consensus predictions all cluster around the same insight: the federal scheduling apparatus — DEA, FDA, the NDA procedural queue — is not a wall that advocacy or cultural momentum can breach directly. Psilocybin remains Schedule I through at least 2028 at 83% probability, not because science is failing, but because the procedural sequence (NDA approval → FDA recommendation → DEA rescheduling) has a minimum clock that no amount of bipartisan enthusiasm shortens. What is forming beneath this friction, however, is a parallel architecture: psychedelic therapy provisions advancing as riders to the NDAA or VA appropriations at 73% probability, neuroplasticity mechanistic papers landing in Nature and Cell family journals at 74%, and the scientific credibility calculus shifting institutionally even as the regulatory clock runs its course. The highest trajectory available here is not a dramatic breakthrough of the scheduling wall — it is the steady construction of the scaffolding that will make that wall structurally untenable by 2028 and beyond.
The human beings inside this story are not waiting for 2028. They are veterans who have already traveled to clinics in Mexico for ibogaine, patients cycling through their fourth antidepressant failure, families watching a loved one refuse treatment because what is available does not work. The 73% likelihood of ibogaine veteran provisions advancing through defense authorization channels represents something specific for them: not a symbolic victory, but VA-supervised access — imperfect, slower than open access, but real, documented, and replicable. For the patient sitting in a ketamine clinic today, watching Spravato's insurance coverage remain inconsistent and IV infusion remain out-of-pocket, the expanding clinical infrastructure and the incoming mechanistic publications matter because they build the evidentiary case that eventually compels payer coverage. The highest positive outcome genuinely available from here is not a single approval event — it is a cascade of smaller structural shifts, each one lowering a barrier that has been holding people outside the door of their own healing.
What is being called in cannot be called back. The currents forming in legislation, in research, in culture — OOTW reads them daily, so you don't have to navigate them alone.
The medicine is older than the fear. The healing is older than the wound.
85%
Psilocybin stays illegal at federal level through 2028
The U.S. federal government will keep psilocybin classified as Schedule I (most dangerous, no medical use) through the end of 2028. This matters because even if your state allows it, federal law still applies — you can still face federal charges, and banks won't touch businesses selling it. Moving psilocybin to a lower schedule requires the FDA (the U.S. drug regulator) to approve it as medicine first, then the DEA (the federal drug enforcement agency) to officially change its category, a process that takes years even after FDA approval.
→ Psilocybin won't move off the highest federal illegal classification before 2029 because no FDA drug approval is on track to trigger the DEA review process.
Resolves: 2028-12-31 · USA
REGULATION
the precise call ▾
Psilocybin remains federally Schedule I in the USA through December 31, 2028.. Federal rescheduling requires an FDA-approved NDA triggering a DEA scheduling review — no psilocybin NDA has been approved or is imminently expected. The procedural queue (FDA recommendation → DEA rulemaking → public comment period) alone takes 18-24+ months from any NDA approval. DEA has demonstrat
72%
Only Oregon and Colorado approve legal psilocybin therapy by 2028
No other U.S. state will pass a law creating a legal framework for people to access psilocybin therapy (not just decriminalization, but an actual licensed system) before January 2028. This matters because it determines whether your state offers any legal route to the treatment. Oregon and Colorado are moving slowly and hitting real problems setting up their systems, which is cooling other states' enthusiasm. Most states are in a 'let's wait and see how this goes' mode rather than drafting their own laws.
→ Only two states will have legal psilocybin therapy frameworks in place by 2028 because the others are watching Oregon and Colorado's rollout before committing.
Resolves: 2027-12-31 · USA
REGULATION
the precise call ▾
No U.S. state beyond Oregon and Colorado enacts a legal therapeutic psilocybin access framework (not just decriminalization) signed into law before January 1, 2028.. Oregon's Measure 109 implementation has been slower and more contentious than proponents projected, dampening enthusiasm in other state legislatures. Colorado's Prop 122 framework is still standing up infrastructure. Most states watching these rollouts are in 'wait and see' mode. Ballot initiative p
65%
Three major science journals publish psychedelic brain research in 2026
Three or more papers explaining exactly how psychedelics change the brain will appear in the world's most prestigious science journals (Nature Neuroscience, Nature Medicine, Cell, or Neuron) in calendar year 2026. This matters because these papers establish the biological mechanism — the proof that these drugs actually rewire brain circuits in real, measurable ways. This evidence builds the case for medical use and attracts serious research funding.
→ Top-tier neuroscience journals will publish at least three major studies on how psychedelics change the brain in 2026.
Resolves: 2026-12-31 · Global
RESEARCH
the precise call ▾
At least three peer-reviewed papers on psychedelic neuroplasticity mechanisms are published in Nature-family or Cell-family journals in calendar year 2026.. Nature Neuroscience, Nature Medicine, Cell, and Neuron have each published high-impact psychedelic mechanistic work in 2023-2025. Johns Hopkins, Imperial College London, and Stanford all have mature mechanistic pipelines. The threshold of 'three papers across the entire Nature/Cell portfolio in a fu
62%
A Phase 3 psychedelic trial hits its main goal by late 2026
At least one large final-stage clinical trial testing psilocybin for depression or MDMA (a related psychedelic) for PTSD will report that the drug actually works as hoped by the end of 2026. This matters because Phase 3 trials are the final hurdle before the FDA decides whether to approve a drug for doctors to prescribe. If one succeeds, it proves the drug works, brings approval closer, and validates the whole industry's approach.
→ One major final-stage clinical trial will report that psilocybin or MDMA works for depression or trauma by late 2026.
Resolves: 2026-12-31 · USA
RESEARCH
the precise call ▾
At least one Phase 3 psychedelic trial (psilocybin for MDD or a supplemental MDMA-PTSD study) reports a statistically significant primary endpoint result by December 31, 2026.. COMPASS Pathways COMP360 Phase 3 MDD trial (COMP005) is actively enrolling with readout plausible in 2026. Usona Institute's psilocybin MDD trial is in Phase 3. Effect sizes in Phase 2 psilocybin MDD studies were large (Cohen's d ~0.8-1.0), giving meaningful probability of replication. Predicting 'a
57%
Congress funds psychedelic research for veterans by late 2026
The U.S. Congress will approve money to fund psychedelic research for veterans — likely by tucking it into a must-pass military spending bill (the National Defense Authorization Act, or NDAA) or a Veterans Administration budget bill by mid-December 2026. This matters because Congress has already done this twice (in 2022 and 2023), showing veteran psychedelic research has real legislative support. Money means trials start, evidence accumulates, and veterans get earlier access to potential treatments.
→ Congress will likely approve federal funding for veterans' psychedelic research by the end of 2026 because it has done so before and has the political support.
Resolves: 2026-12-15 · USA
LEGISLATION
the precise call ▾
Psychedelic therapy research provisions are included in the FY2027 NDAA or a VA appropriations bill passed by December 15, 2026.. Congress has repeatedly used the NDAA as a vehicle for veteran-focused psychedelic research provisions (e.g., 2022 and 2023 NDAA included psychedelic research funding language). Must-pass status of NDAA makes it the realistic path for niche medical policy. Veteran advocacy coalitions are organized a